Oxford, UK – 7 November 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that the first patient has been treated in TRIST, a pivotal multi-centre Phase III trial of TroVax®, the Company’s novel cancer immunotherapy, in patients with advanced or metastatic renal cell carcinoma (RCC).
